Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets
Purpose: To evaluate the pharmacological effects of propranolol treatment of patients with central serous chorioretinopathy (CSCR) over 4 months.<b> </b>Results: Among the 89 male and 31 female patients, the mean BCVA decreased to 0.42 ± 0.08 logMAR during CSCR attacks. Oral propranolol...
Main Authors: | Li-Chai Chen, Jui-Wen Ma, Po-Chuen Shieh, Chi-Ting Horng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/11/336 |
Similar Items
-
Effects of propranolol in patients with central serous chorioretinopathy
by: Farzan Kianersi, et al.
Published: (2008-06-01) -
Endogenous Hypercortisolism in recurrent Central Serous Chorioretinopathy
by: Sushmita Mukherji, et al.
Published: (2021-02-01) -
Current Choroidal Imaging Findings in Central Serous Chorioretinopathy
by: Gideon Nkrumah, et al.
Published: (2020-10-01) -
Subretinal hyperreflective material in central serous chorioretinopathy
by: Niroj K Sahoo, et al.
Published: (2020-01-01) -
Efficacy of nanosecond laser treatment in central serous chorioretinopathy with and without atrophy of retinal pigment epithelium
by: Hakan Kaymak, et al.
Published: (2020-06-01)